Biologics production is one of the industries that is ripe for a manufacturing breakthrough, and would greatly benefit humanity.
The current best option we have for combating heart disease and lowering cholesterol are monoclonal antibodies (PCSK9 inhibitors), and a similar trajectory is developing with sarcopenia and obesity biologics (Bimagrumab).
Manufacturability is treated as an afterthought right now, but as we’ve seen in other industries, if you can bring some of those constraints earlier into the process it can have serious economic implications.
The opportunity for manufacturing innovation is growing, as the next generation of monoclonal antibodies are even more difficult to produce at scale.
Thanks for posting this here! And surprising its attracting attention, I have to imagine that the TAM for 2-hour-long biologics-manufacturing podcasts is small :)
If you're more interested in this person's work, his website is here: https://www.iku.bio/
Biologics production is one of the industries that is ripe for a manufacturing breakthrough, and would greatly benefit humanity.
The current best option we have for combating heart disease and lowering cholesterol are monoclonal antibodies (PCSK9 inhibitors), and a similar trajectory is developing with sarcopenia and obesity biologics (Bimagrumab).
Manufacturability is treated as an afterthought right now, but as we’ve seen in other industries, if you can bring some of those constraints earlier into the process it can have serious economic implications.
The opportunity for manufacturing innovation is growing, as the next generation of monoclonal antibodies are even more difficult to produce at scale.
Thanks for posting this here! And surprising its attracting attention, I have to imagine that the TAM for 2-hour-long biologics-manufacturing podcasts is small :)
If you're more interested in this person's work, his website is here: https://www.iku.bio/